Previous studies have established that the cell-cell adhesion molecule-1 (CEACAM1, previously known as C-CAM1) functions as a tumor suppressor in prostate cancer and is involved in the regulation of prostate growth and differentiation. However, the molecular mechanism that modulates CEACAM1 expression in the prostate is not well defined. Since the growth of prostate epithelial cells is androgen-regulated, we investigated the effects of androgen and the androgen receptor (AR) on CEACAM1 expression. Transient transfection experiments showed that the AR can enhance the Ceacam1 promoter activity in a ligand-dependent manner and that the regulatory element resides within a relatively short ( −249 to − 194 bp) segment of the 5%-flanking region of the Ceacam1 gene. This androgen regulation is likely through direct AR-promoter binding because a mutant AR defective in DNA binding failed to upregulate reporter gene expression. Furthermore, electrophoretic mobility shift assays demonstrated that the AR specifically binds to this sequence, and mutation analysis of the potential ARE sequences revealed a region within the sequence that was required for the AR to activate the Ceacam1 gene. Therefore, the regulation of Ceacam1 gene expression by androgen may be one of the mechanisms by which androgen regulates prostatic function.
Introduction
The cell -cell adhesion molecule-1 (C-CAM1), recently renamed CEACAM1 (Beauchemin et al., 1999) , is a member of the immunoglobulin supergene family (Lin and Guidotti, 1989; Lin et al., 1991) . CEACAM1 is mainly expressed in epithelial cells of many different tissues, including the prostate (Odin et al., 1988) . Loss of CEACAM1 expression is an early event in prostate cancer progression Pu et al., 1999) , suggesting that this molecule may play an important role in prostate tumorigenesis. Consistent with this hypothesis, expression of CEACAM1 in prostate cancer cells can suppress their tumorigenicity in vivo (Estrera et al., 1999; Hsieh et al., 1995; Luo et al., 1999) . These observations suggest that CEACAM1 functions as a tumor suppressor in prostate cancer.
The prostate is an androgen-dependent organ, as androgen is the major regulator of prostate development, growth, and secretory function. Induction of prostate involution using androgen ablation is one of the most effective treatments of late-stage prostate cancer. Since CEACAM1 is a tumor suppressor in prostate cancer, it is important to know whether expression of CEACAM1 in the prostate is regulated by androgen.
The rat Ceacam1 promoter belongs to the GC-rich class of TATA-less promoters (Najjar et al., 1996) . Deletion and substitution analyses have revealed that the three proximal Sp1 binding sites are essential for basal transcription of the Ceacam1 gene. In addition, Najjar et al. (1996) have shown that Ceacam1 promoter activity is stimulated 2-3-fold by insulin, dexamethasone, and cyclic adenosine monophosphate treatment. However, the effect of androgen on Ceacam1 promoter activity has not been examined. Therefore, in this study, we examined whether the androgen receptor (AR) regulates Ceacam1 promoter activity.
Materials and methods

Plasmid constructions
The 5%-flanking region of the rat Ceacam1 gene was cloned as described previously (Najjar et al., 1996) . Nucleotides were numbered relative to +1 at the ATG translation initiation codon and labeled as negative numbers to reflect their position upstream (5%) of the ATG site. Using polymerase chain reaction (PCR), 5% deletion products (−1609, − 439, −249, − 194, − 147, −131, −124 and −112 bp) of the Ceacam1 gene were synthesized and subcloned at the XhoI and HindIII sites of the pGL3-BASIC plasmid (Promega, Madison, WI) (Najjar et al., 1996) .
The mutants −249pLucARE-1Mut and −249pLuc-ARE-2Mut were generated by site-directed mutagenesis of the − 249pLuc vector using PCR. Oligo c 305 (reverse primer; AAGCTTTTCTCTTGGGGAAGA) and oligo c 306 (forward primer; CTCGAGATGTTCTA-GAACAATGAACCGAAAAGAGATCCCGCGAA-GGATGGGAGGACAGCA) were used as primers to introduce substitutions into the ARE-1 region, while oligo c 307 (forward primer; GCTAGCCCGGGCTC-GAGAGTCGACAGAACAATGAACCGAAAA) and oligo c305 were used to introduce substitutions into the ARE-2 region; the sequences that were changed from the wild type are underlined. After these PCR products were sequenced to confirm the mutations, they were subcloned at the XhoI and HindIII sites of the pGL3-BASIC plasmid. The construction of the reporter plasmid harboring two androgen response elements and a TATA box driving the luciferase gene (p[ARE]2-E1b-luc) has been described previously .
The human AR cDNA expression vector (pAR 0 ) was constructed using the simian virus 40 (SV40) early promoter and the rabbit b-globin polyadenylation signal as described previously (Brinkmann et al., 1989) . The AR mutant expression vector pAR64, in which the first zinc finger in the AR was disrupted by the replacement of two cysteines with serine and phenylalanine, was constructed as described by Jenster et al. (1993) .
Additionally, the superactive AR expression vector pcDNA-AR 0 p65 was constructed by inserting the Asp718-(filled in with the Klenow fragment) and SacII digested fragment of pcDNA-AR LBD -p65 into the HpaI and SacII digested pcDNA-AR 0 mcs vector (Sui et al., 1999) . This resulted in the generation of a fusion protein containing the wild-type AR fused with the transactivation domain of p65/RelA.
Culture and transfection of HeLa cells
HeLa human cervical carcinoma cells (American Type Culture Collection, Manassas, VA) were maintained in minimal essential medium supplemented with 10% (v/v) fetal calf serum (FCS). These cells (50 000) were plated in a 12-well plate with 10% (v/v) charcoalstripped FCS 24 h before transfection. The cells were transfected with 0.3 mg of both luciferase reporter plasmid containing a Ceacam1 promoter fragment and a receptor plasmid containing either wild-type (pAR 0 ) or modified AR (pAR64 or pcDNA-AR 0 p65) per well using Lipofectin (Life Technologies, Inc., Grand Island, NY) according to the manufacturer's guidelines. About 24 h after transfection, the cells were washed and fed with medium containing charcoal stripped serum with or without R1881 (17a-methyltrienolone; NEN Life Science Products, Boston, MA), and the incubations were continued for an additional 24 h. The cells were then lysed in 200 ml lysis buffer, and the luciferase activity was measured using a luciferase assay system (Promega). The experiments were performed in triplicate.
Electrophoretic mobility shift assay (EMSA)
EMSA was carried out using a bandshift assay system (Promega). Oligonucleotides having sequences corresponding to the region between −194 to − 249 bp of the Ceacam1 promoter were synthesized by Genosys (Houston, TX) and used as probe. In addition, oligonucleotides containing the AR consensus sequence were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and used as competitors. The plasmid pRSET-GST-AR DBD containing a sequence from the AR DNA binding domain fused to GST was constructed by inserting 0.3 kb of the Klenow-treated RsrII/XbaI digested ARDBD fragment from AR126 (Jenster et al., 1995) into the Klenow-treated NcoI/HindIII digested pRSET-GST-SRC782-1139 vector . The GST-fusion protein containing the AR DNA binding domain (GST-AR DBD ) was expressed and purified from Escherichia coli BL21(lDE3), and 100 ng of GST-AR DBD protein was used for EMSA. Purified GST protein was used as a negative control.
Statistic analysis
Student's t-test was used to examine R1881 effects on different types of mutation. We chose the ratio of promoter activities in the presence and absence of R1881 as a dependent variable to avoid variation in basal activity between different experiments.
Results
Localization of an androgen-responsi6e region in the Ceacam1 promoter
To examine the effect of AR on Ceacam1 promoter activity, we first tested cell lines that express AR. Although LNCaP cells, which were isolated from the lymph node metastasis of a prostate cancer patient (Horoszewicz et al., 1983) , were shown to express AR, the transfection efficiency in this cell line was very low (data not shown). Another prostatic cell line that express AR is NbE cell. NbE cell is a cell line derived from the ventral prostate of Noble rat and is shown to express AR (Chung et al., 1989) . We found that the reporter plasmid containing two androgen response elements (p[ARE] 2 -E1b-luc) could not respond to R1881 stimulation when transfected into the NbE cells (data not shown). However, this reporter was activated 90-340-folds by R1881 when it was co-transfected with a wild type AR plasmid in the NbE cells (data not shown). This observation suggested that the AR in NbE cells was not functional. The reason for AR dysfunction in NbE cells is not known. Previous studies by Jenster et al. (1995) and Sui et al. (1999) have shown that HeLa cells co-transfected with AR and promoter constructs were suitable for AR related studies. As a result, we chose to use HeLa cells co-transfected with AR for this study.
Ceacam1 promoters with different lengths that were constructed by 5% deletion were cloned in front of the luciferase gene in the reporter plasmid. Each of these plasmids was transiently cotransfected with the AR expression vector pAR 0 into HeLa cells; the reporter plasmid containing two androgen response elements and a TATA box derived from the E1b gene (p[ARE]2-E1b-luc) was used as a positive control. In the absence of the androgen analogue R1881, the 1609 bp Ceacam1 promoter mediated a 106-fold increase in reporter gene Fig. 1 . Regulation of CEACAM1 expression by androgen. A series of reporter plasmids containing Ceacam1 promoter fragments having different 5% deletions were cotransfected with a wild-type AR plasmid (pAR 0 ) into HeLa cells. About 24 h after transfection, the cells were incubated with (+ ) or without ( − ) 1 nM R1881. The luciferase activity of these cell lysates was determined as described in Section 2. This experiment was repeated eight times with triplicate transfections for each construct and similar results were obtained. Results from one of these experiments were shown and the luciferase activities were reported as the average 9 S.D. in relative light units of triplicate transfections. Statistic analysis was used to determine whether there was difference between the R1881 treated and untreated groups. Only −249pLuc construct showed statistically significant difference and the P value for − 249pLuc is shown. Fig. 2 . Effect of an AR mutation on its ability to activate the Ceacam1 promoter. Cells were transfected with the −249pLuc Ceacam1 promoter together with a wild-type AR (pAR 0 ) or mutant AR (pAR64) plasmid, respectively. The data are presented as the mean 9S.E. of three independent experiments. Statistic analysis was used to determine whether there was difference between the R1881 treated and untreated groups.
The P values for each group are shown. expression as compared with the reverse-oriented Ceacam1 promoter fragment (Fig. 1) . Deletion of the region between nt − 1609 and − 439 induced a slight increase in the basal promoter activity (Fig. 1) , suggesting that this region may contain potential down-regulators. Deletion of the Ceacam1 promoter up to − 194 bp did not abolish its ability to induce luciferase expression, while deletion up to − 147 bp markedly reduced its promoter activity. This result suggested that a minimal promoter is located within the first 194 bp 5% from Ceacam1's translation start site. We next investigated whether androgen had an effect on the Ceacam1 promoter. As shown in Fig. 1 , the plasmid containing the Ceacam1 promoter region from − 249 to − 21 bp exhibited a 2.5-fold increase in luciferase activity upon the addition of the androgen analogue R1881. In contrast, no significant hormone response was observed with plasmids containing the entire 1609, 439, or 194 bp segment proximal to the translation start site. These observations suggested that the region from − 249 to − 194 bp in the Ceacam1 gene may contain an androgen-regulated sequence.
Direct binding of the AR to the promoter sequence
The AR is a 110-112 kDa protein containing transcriptional activation domains in its N-terminal region, a centrally located DNA binding domain, and the ligand binding domain at its C-terminus (Jenster et al., 1991) . To test whether activation of the Ceacam1 promoter by androgen is due to direct interaction between it and the AR, we investigated the effect of a mutant AR, AR64, which is defective in DNA binding (Jenster et al., 1993) , on Ceacam1 promoter activity. In contrast to the wild-type AR, AR64, when cotransfected with −249pLuc into HeLa cells, did not show significant hormone induction (Fig. 2) . Similarly, p[ARE]2-E1b-Luc lost its response to R1881 stimulation. These results suggest that activation of the Ceacam1 promoter by the wild-type AR requires its DNA binding domain; thus, AR may bind directly to Ceacam1 promoter.
In addition, EMSA was used to determine whether the AR can bind to the promoter sequence. A doublestranded oligonucleotide containing the promoter sequence from − 249 to −194 bp was used in the assay. Fig. 3 shows that the AR DNA binding domain can bind to the oligonucleotide (− 249 to − 194 bp) and that the binding can be specifically competed by the unlabeled corresponding oligonucleotide duplexes, as well as an unlabeled oligonucleotide containing the AR consensus sequence (Roche et al., 1992) . This observation suggested that the AR binds specifically to the Ceacam1 promoter sequence.
Identification of AR-interacting sites
Using a DNA binding site-selection assay, Roche et al. (1992) determined a consensus AR DNA binding site for the AR. Two regions in the Ceacam1 promoter, located at −215 to − 220 bp and − 243 to − 248 bp, respectively, showed homology to the consensus halfsite sequence and could be responsible for androgen induction of the −249pLuc reporter activity (Fig. 4) . These two potential AR binding sites (ARE-1 and ARE-2) were mutated to see if they are indeed involved in androgen regulation. The effect of mutating ARE-1 or ARE-2 on the promoter activity was examined. Mutations of ARE-1 did not cause a significant change in the Ceacam1 promoter's response to R1881, while mutation of ARE-2 completely abolished the response (Fig. 4) . In addition, mutating both ARE-1 and ARE-2 had a similar effect to that of mutating ARE-2 alone. These observations suggested that only ARE-2 is involved in the androgen regulation of Ceacam1 promoter activity.
A mutational analysis of potential ARE sites was also performed using a superactive AR containing the AR fused with the transactivation domain of p65/RelA (Schmitz and Baeuerle, 1991) . As part of the AR 0 p65 fusion protein, the p65 activation domain can recruit additional coactivators and proteins of the preinitiation complex resulting in amplification of AR-mediated transcriptional signals. As shown in Fig. 5A , the −249 bp Ceacam1 promoter activity showed a 5-6-fold increase in response to R1881 stimulation with the superactive AR in contrast to a 2-3-fold increase in response to R1881 stimulation with the wild-type AR. Such an enhancement of reporter activity was used to further confirm the mutational analysis. In the presence of the superactive AR, mutation of ARE-1 resulted in a 4-fold increase in luciferase activity in response to R1881. As observed with wild-type AR, R1881 treatment did not increase the promoter activity of the ARE-2 mutant or combined ARE-1/ARE-2 mutant. These observations further confirmed that the AR only requires ARE-2 to stimulate Ceacam1 promoter activity.
Discussion
Androgen is the most important factor that regulates prostate growth and differentiation. A series of genes that have functions related to cell-growth modulation have been shown to be regulated by androgen in prostate cells. It was shown that androgen can directly or indirectly upregulate growth factors such as epidermal growth factor (Hiramatsu et al., 1988; Nishi et al., 1996) , keratinocyte growth factor (Fasciana et al., 1996; Peehl and Rubin, 1995; Rubin et al., 1995; Yan et al., 1992) , and basic fibroblast growth factor (Katz et al., 1989; Zuck et al., 1992) , leading to epithelial-cell proliferation. In addition, transforming growth factor b, which has been linked to programmed cell death, is induced upon androgen withdrawal (Kyprianou et al., 1990) . Regulation of growth hormones and apoptotic factors may contribute to the growth of the prostate. On the other hand, androgen upregulation of insulinlike growth factor binding proteins (IGFBP) could make the potent prostate mitogens IGF-I and IGF-II unavailable for growth induction (Gregory et al., 1999) . Cell-cycle regulatory proteins such as cdk2, cdk4, cyclin D3, cyclin A, p21CIP1/WAF-1, p27kip1, and p16 were also found to be regulated by androgen (Gregory et al., 1998; Knudsen et al., 1998; Kokontis et al., 1998; Lu et al., , 1997 . These diverse androgen-regulated events result in the maintenance of prostate homeostasis; disruption of these intricately balanced events may lead to prostate cancer initiation and progression.
In the present study, we showed that Ceacam1, a tumor suppressor gene, can, under defined circumstances and/or in a specific cellular context, be regulated by androgen. Specifically, androgen could up-regulate CEACAM1 expression in a ligand-dependent manner when tested in vitro. This androgen regulation is controlled by only one of the two half-sites of the AR consensus sequence (Roche et al., 1992) . A similar event was also observed by Dai and Burnstein (1996) , who showed that the presence of one half-site of the AR consensus sequence is sufficient to upregulate the promoter of the AR gene by the AR. This half-site interaction may not provide as strong an activity as that provided by the full consensus sequence in the promoter is shown. Two half-sites of putative androgen-responsive elements (ARE-1 and ARE-2) are underlined; the mutated sequence of the two elements is shown. Cells were transfected with reporter plasmids containing the − 249 bp promoters, whose putative ARE-1 or ARE-2 sequence was mutated as described in Section 2. The luciferase activity is presented as a percent of that of the corresponding plasmid containing no mutation and without R1881 treatment. The data are presented as the mean 9S.E. of three independent experiments. Statistic analysis was used to determine whether there was difference between the R1881 treated and untreated groups. The P values for each group are shown. probasin promoter (Kasper et al., 1994) and PSA promoter (Zhang et al., 1997) . In addition, the longer Ceacam1 promoter, i.e. the 439-bp segment, did not show ligand-dependent regulation by androgen, suggesting that other regulatory mechanisms may be present upstream of the promoter region and may influence the interaction of the AR with the Ceacam1 proximal promoter region. Thus, the regulation of CEACAM1 expression by the AR is complex and may depend on its cellular context. In this regard, it is interesting to note that in the rat, CEACAM1 is mainly expressed in the dorsal lobe but not the ventral lobe of the prostate, although the AR is expressed in both prostate lobes (Makarovskiy et al., 1999) . In addition, using castration-induced prostate involution followed by administration of androgen, we have previously shown that expression of CEACAM1 in the rat ventral prostate was negatively regulated by androgen in vivo, while its expression in the dorsal prostate showed no response to androgen manipulation in vivo (Hsieh and Lin, 1994; Makarovskiy et al., 1999) . In the mouse prostate, on the other hand, increased CEACAM1 expression was detected in the dorsal prostate lobe following castration . In the present study, we found that androgen could up-regulated CEA-CAM1 expression in a ligand-dependent manner, although up-regulation of CEACAM1 expression by androgen was observed only with a relatively short promoter (bp −294 to − 197). Together, these observations suggest that the regulation of CEACAM1 expression by androgen in vivo is a complex process. Although the AR has a positive effect on the proximal region of the Ceacam1 promoter, it may have a negative effect on the other region of the Ceacam1 promoter. AR regulation of CEACAM1 expression is, therefore, influenced by the cellular context and possibly the stromal components of the prostate. The interactions between prostatic epithelial and stromal components have been shown to contribute to androgen-dependent regulation of prostate growth and differentiation (Chung, 1995; Cunha et al., 1987) . As a result, although direct interactions between AR and Ceacam1 promoter may contribute to androgen regulation of CEACAM1 expression, other factors including signals from stromal-epithelial interactions may also influence CEACAM1 expression in vivo.
Primary prostate cancers are largely dependent on androgens for growth and survival. Therefore, the disease responds favorably to androgen ablation and antiandrogen therapy in most patients. However, virtually all patients will relapse with clinically defined androgenindependent cancer. Previously, the role of CEACAM1 in androgen-dependent and androgen-independent prostate cancer was studied by examining the patterns of CEACAM1 expression during prostate cancer initiation, progression, and metastasis in the transgenic adenocarcinoma of mouse prostate (TRAMP) model, which was generated by using the rat probasin pro-moter to target the SV40 large T antigen specifically to the mouse prostate (Greenberg et al., 1995) . In the TRAMP mice, immunohistochemical staining using polyclonal antibody Ab669 against CEACAM1 revealed that the CEACAM1 protein was expressed in normal prostate epithelia, as well as low-grade prostate intraepithelial neoplasia (PIN); the expression was uniform on the luminal surfaces of these epithelia. CEA-CAM1 expression was noticeably reduced and the staining pattern was heterogeneous in some cases of high-grade PIN, and CEACAM1 staining was generally absent from prostate cancer and metastatic lymph nodes. Androgen-independent prostate cancer and its metastases generated in castrated TRAMP mice were also CEACAM1 negative . Since loss of CEACAM1 expression occurred before the development of androgen-independent tumors, it is likely that the AR regulation of CEACAM1 expression is not related to the loss of CEACAM1 during prostate cancer progression.
Other factors that have been shown to have an effect on the Ceacam1 promoter include the upstream stimu- Fig. 5 . Activation of Ceacam1 promoter activity by a superactive AR (AR 0 p65). (A) The Ceacam1 promoter transcription activity was examined using cotransfection of the Ceacam1 promoter reporter construct ( −249pLuc) and the wild-type or superactive AR expression plasmid (pAR 0 p65) into HeLa cells. The luciferase activity was determined from cell lysates of transfected cells as described in Section 2. This experiment was repeated six times with triplicate transfections for each construct and similar results were obtained. Results from one of these experiments were shown and the luciferase activities were reported as the average 9S.D. in relative light units of triplicate transfections. (B) Effect of superactive AR on mutant Ceacam1 promoter transcription activity. The luciferase activity is presented as a percent of the luciferase activity without R1881 treatment. The data are presented as the mean 9 S.E. of three independent experiments. Statistic analysis were performed as described in Section 2 to compare the R1881-treated and untreated groups for each construct, and the P values for each group are shown. latory factor and hepatocyte nuclear factor-4 (Hauck et al., 1994) . Also, Chen et al. (1996) showed that treatment of HT-29 cells with interferon-g (IFN-g) upregulated CEACAM1 expression. This was due to the ability of IFN-g to upregulate the expression of IRF-1, which, by binding to the interferon stimulated response element located in the human Ceacam1 promoter, activated Ceacam1 transcription. Thus, the regulation of CEACAM1 expression is a combination of different transcriptional factors, one of which is the AR.
